- Current report filing (8-K)
October 29 2009 - 4:15PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): October 29,
2009
|
Idenix
Pharmaceuticals, Inc.
|
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
|
000-49839
|
45-0478605
|
|
(State
or Other Juris-
diction
of Incorporation
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
|
|
|
|
60
Hampshire Street
Cambridge,
MA
|
02139
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: 617-995-9800
|
|
|
(Former
Name or Former Address, if Changed Since Last
Report)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (
see
General Instruction A.2.
below):
¨
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
2.02. Results of Operations and Financial Condition
On October 29, 2009, Idenix
Pharmaceuticals, Inc. (the “Company”) announced its financial results for the
quarter ended September 30, 2009. The full text of the press release
issued in connection with the announcement is furnished as Exhibit 99.1 to this
Current Report on Form 8-K.
On
October 29, 2009, the Company also announced that Novartis Pharma AG, its
collaboration partner, has notified the Company that it has decided not to
exercise its option to license IDX184, a novel liver-targeted prodrug of
2'-methyl guanosine nucleotide, for the treatment of HCV. As a
result, the Company retains the worldwide rights to develop, commercialize and
license IDX184 without any further obligation to Novartis. The Company plans to
seek a partner that will assist in the further development and commercialization
of the drug candidate. The full text of the press release issued in connection
with the announcement is furnished as Exhibit 99.2 to this Current Report on
Form 8-K.
The information in the first paragraph
of this Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or
otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933 or the
Exchange Act, except as expressly set forth by specific reference in such a
filing.
Item
9.01. Financial Statements and Exhibits
The
following exhibit relating to Item 2.02 shall be deemed to be furnished, and not
filed:
|
|
99.1
|
Press
Release, “Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2009
Financial Results,” dated October 29,
2009.
|
|
|
99.2
|
Press
Release, “Idenix Retains Worldwide Rights to Develop and Commercialize
IDX184 for the Treatment of HCV,” dated October 29,
2009
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
Idenix
Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Ronald C. Renaud, Jr.
|
|
|
|
|
Ronald
C. Renaud, Jr.
Chief
Financial Officer
|
|
EXHIBIT
INDEX
|
Exhibit
No.
|
Description
|
|
|
|
|
99.1
|
Press release
“Idenix
Pharmaceuticals Reports Third Quarter and Nine Month 2009 Financial
Results,” dated October 29, 2009.
|
|
|
|
|
99.2
|
Press
Release, “Idenix Retains Worldwide Rights to Develop and Commercialize
IDX184 for the Treatment of HCV,” dated October 29,
2009.
|
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jul 2023 to Jul 2024
